FDA Alerts

By Reuters Staff

The FDA has approved a new opioid that features specific properties designed to deter, but not prevent, abuse.

The FDA has approved a new option for patients with relapsing multiple sclerosis and inadequate response to other treatment options.

The FDA has approved a new once-daily combination drug for the treatment of type 2 diabetes.

Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with meningitis B, hemophilia A, and non-valvular atrial fibrillation.

The FDA granted fast track priority review and approved two new treatments for idiopathic pulmonary fibrosis ahead of originally intended approval dates.

Primary care practitioners should be aware of new FDA approvals for treating hepatitis C, peripheral artery disease, and chemotherapy-related nausea.

By...

Primary care practitioners should be aware of new FDA approvals that may be useful when treating patients with COPD, melanoma, and Crohn's disease.

The FDA has approved Trulicity, a new injection for glycemic control in patients with type 2 diabetes.